Search
Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalIt has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UsePerflubutane
go.drugbank.com/drugs/DB12821ApprovedInvestigationalWithdrawnIt is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.
Categories: Compounds used in a research, industrial, or household settingSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalThese include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Cefapirin
go.drugbank.com/drugs/DB01139ApprovedVet approvedProduction for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653] … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.
Pafolacianine
go.drugbank.com/drugs/DB15413ApprovedInvestigational[L39332] The longer wavelength allows for deeper penetration of the fluorescent light through tissues for better imaging and detection of tumours. … [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.
Categories: Compounds used in a research, industrial, or household settingLindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnLindane is still allowed for pharmaceutical use until 2015. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical
Categories: Compounds used in a research, industrial, or household settingAdenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
Thiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approvedA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state.